keyword
MENU ▼
Read by QxMD icon Read
search

Acute Myelogenic Leukemia

keyword
https://www.readbyqxmd.com/read/30305967/successful-antimicrobial-treatment-of-phlegmonous-gastritis-a-case-report-and-literature-review
#1
Madiha Iqbal, Rabia Saleem, Salman Ahmed, Prachi Jani, Salvador Alvarez, Han W Tun
Phlegmonous gastritis is an uncommon acute bacterial infection of the stomach that carries a fatal prognosis in spite of the advent of antibiotics. A high index of suspicion is required in patients with risk factors. An immunocompromised state is identified as one of the most important risk factors. We hereby report a case of successful antimicrobial treatment of phlegmonous gastritis in a patient who was receiving intensive chemotherapy for acute myelogenous leukemia. We have also carried out a review of literature over the past ten years...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/30295244/-effect-of-pd-l1-expression-on-activity-of-nk-killing-aml-cell-lines-and-its-mechanisms
#2
Yan-Feng Liu, Peng-Cheng He, Mei Zhang
OBJECTIVE: To expolore the effect of programmed death receptor ligand 1 (PD-L1) expression level on killing effect of different cell lines of acute myeloid leukemia (AML) and its possible mechanism. METHODS: Peripheral blood from healthy individuals was collected routinely; NK cells were isolated using immunomagnetic beads; PD-L1 expression level was detected by flow cytometry; the killing effect of NK cells on acute myelogenous leukemia cell lines was evaluated with LDH release method and monoclonal antibody blocking experiment; the expression levels of IFN-γ and IL-2 in the supernatants from the co-cultured effector/targer cells were measured by ELISA...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/30260758/improved-survival-by-adding-lomustine-to-conventional-chemotherapy-for-elderly-patients-with-aml-without-unfavorable-cytogenetics-results-of-the-lam-sa-2007-filo-trial
#3
Arnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, Pierre-Yves Dumas, Jacques Delaunay, Caroline Bonmati, Romain Guièze, Isabelle Luquet, Pascale Cornillet-Lefebvre, Eric Delabesse, Jean-Christophe Ianotto, Mario Ojeda-Uribe, Mathilde Hunault, Anne Banos, Luc Matthieu Fornecker, Marc Bernard, Eric Jourdan, Norbert Vey, Hacene Zerazhi, Yosr Hishri, Ariane Mineur, Julien Asselineau, Roselyne Delepine, Jean-Yves Cahn, Norbert Ifrah, Christian Récher
PURPOSE: Acute myeloid leukemia (AML) in elderly patients has a poor prognosis. In an attempt to improve outcome for these patients, the prospective open-label phase III LAM-SA 2007 (Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old) trial randomly assigned patients to a standard induction regimen with lomustine added or to a consolidation regimen with cytarabine and idarubicin...
September 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30245563/carbapenem-resistant-klebsiella-pneumoniae-in-a-febrile-neutropenia-patient-with-acute-myelogenous-leukemia-after-hematopoietic-stem-cell-transplantation
#4
Satomi Asai, Toshio Ohshima, Hideo Iwashita, Yoshikazu Ishii, Kotaro Aoki, Yuki Minakawa, Shinichiro Machida, Kazuo Umezawa, Kazuhiro Tateda, Hayato Miyachi
No abstract text is available yet for this article.
September 2018: Infectious Diseases in Clinical Practice: IDCP
https://www.readbyqxmd.com/read/30223700/salvage-extracorporeal-membrane-oxygenation-in-induction-associated-acute-respiratory-distress-syndrome-in-acute-leukemia-patients-a-case-series
#5
Nikhil A Huprikar, Matthew R Peterson, Jeffrey D DellaVolpe, Valerie G Sams, James H Lantry, Robert J Walter, Michael B Osswald, Kevin K Chung, Phillip E Mason
BACKGROUND: The prognosis of hematologic malignancies has improved over the past three decades. However, the prognosis in hematologic malignancies with severe acute respiratory distress syndrome has remained poor. Initial reports regarding the utility of extracorporeal membrane oxygenation in hematologic malignancies have been controversial, with limited evaluations of acute leukemia patients supported by extracorporeal membrane oxygenation. METHODS: We conducted a retrospective review of patients with acute leukemia who developed acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation support at our facility from July 2015 through August 2017...
September 17, 2018: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/30198961/importance-of-acute-lymphoblastic-leukemia-type-therapy-for-bilineal-acute-leukemia
#6
Shunsuke Nakagawa, Yasuhiro Okamoto, Yuichi Kodama, Takuro Nishikawa, Takayuki Tanabe, Yoshifumi Kawano
We examined 3 pediatric patients with bilineal acute leukemia. Patient 1 with B-cell acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) with B-ALL dominance responded well to prednisolone and ALL-type induction therapy. Patients 2 and 3 with T-ALL and AML with AML dominance responded poorly to prednisolone. Patient 2 was resistant to AML-type therapy; patient 3 was resistant to ALL-type induction therapy until day 15. However, all 3 patients eventually achieved complete remission after ALL-type induction therapy...
September 5, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/30185627/a-novel-mcl-1-inhibitor-combined-with-venetoclax-rescues-venetoclax-resistant-acute-myelogenous-leukemia
#7
Haley E Ramsey, Melissa A Fischer, Taekyu Lee, Agnieszka E Gorska, Maria Pia Arrate, Londa Fuller, Kelli L Boyd, Stephen A Strickland, John Sensintaffar, Leah J Hogdal, Gregory D Ayers, Edward T Olejniczak, Stephen W Fesik, Michael R Savona
Suppression of apoptosis by expression of anti-apoptotic BCL2-family members is a hallmark of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein (MCL-1), an anti-apoptotic BCL-2 family member, is commonly upregulated in AML cells, and is often a primary mode of resistance to treatment with the BCL-2 inhibitor, venetoclax. Here, we describe VU661013, a novel, potent, selective MCL-1 inhibitor that de-stabilizes BIM/MCL-1 association, leads to apoptosis in AML, and is active in venetoclax-resistant cells and patient derived xenografts...
September 5, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30135464/end-of-life-care-for-older-aml-patients-relapsing-after-allogeneic-stem-cell-transplant-at-a-dedicated-cancer-center
#8
Richard J Lin, Theresa A Elko, Miguel-Angel Perales, Koshy Alexander, Ann A Jakubowski, Sean M Devlin, Parastoo B Dahi, Esperanza B Papadopoulos, Virginia M Klimek, Sergio A Giralt, Judith E Nelson
Older patients with acute myelogenous leukemia (AML) are at increased risk for mortality and morbidity. While allogeneic stem cell transplantation may provide cure in some patients, many still relapse after transplant and are then left with limited therapeutic options and poor survival. Moreover, the quality of the end-of-life care for these patients has not been previously reported. We describe here the end-of-life experience of a cohort of 72 older patients with AML who relapsed after first allogeneic stem cell transplant at our dedicated cancer center...
August 22, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30126588/locally-advanced-cervical-cancer-complicating-pregnancy-a-case-of-competing-risks-from-the-catholic-university-of-the-sacred-heart-in-rome
#9
R De Vincenzo, L Tortorella, C Ricci, A F Cavaliere, G F Zannoni, M G Cefalo, G Scambia, A Fagotti
A case of stage IB2 cervical cancer at 27 weeks of pregnancy, treated with neoadjuvant chemotherapy followed by radical Cesarean hysterectomy with full pelvic and infra-mesenteric lymphadenectomy, and adjuvant chemo-radiation is described. While she remains without disease, her baby was diagnosed with acute myelogenous leukemia. We highlight the pre-operative work-up, treatment options, safety, feasibility, and outcomes for the mother and her fetus.
September 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/30111440/-research-advances-of-molecular-genetic-abnormality-in-myelodysplastic-syndrome-review
#10
Yan-Bin Pang, Ping Wu, Luo-Ming Hua, Xin DU, Jing Wang
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid disorders characterized by ineffective hematopoiesis and increased risk of transformation to acute myelogenous leukemia (AML). The treatment of MDS is highly dependent on the reliability of the prognostic evaluation model. Current clinical prognostic scoring systems are comprised of morphology, pivotal clinical trials and cytogenetic findings. However, none of the available prognostic systems incorporates disease-related molecular abnormalities, such as somatic mutations...
August 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/30108676/diffuse-periostitis-as-the-primary-presenting-radiological-finding-in-an-aml-patient-with-disease-relapse
#11
Raza Mushtaq, David Nolte, Faryal Shareef, Mihra S Taljanovic
Acute myelogenous leukemia is a hematologic malignancy defined by the presence of myeloid blasts causing bone marrow infiltration. Evaluation and workup of acute myelogenous leukemia is based on comprehensive medical history, physical examination, laboratory evaluation, and bone marrow sampling. Magnetic resonance (MR) imaging is the study of choice in the evaluation of this disease including the initial evaluation, treatment follow-up, and complications. Herein, we report a case of relapse of the acute myelogenic leukemia in an adult patient who presented with diffuse periostitis in his lower extremities diagnosed on MR imaging and confirmed on Technetium bone scan, which also showed periostitis along the bilateral humeri...
October 2018: Radiology case reports
https://www.readbyqxmd.com/read/30093396/asxl2-regulates-hematopoiesis-in-mice-and-its-deficiency-promotes-myeloid-expansion
#12
Vikas Madan, Lin Han, Norimichi Hattori, Weoi Woon Teoh, Anand Mayakonda, Qiao-Yang Sun, Ling-Wen Ding, Hazimah Binte Mohd Nordin, Su Lin Lim, Pavithra Shyamsunder, Pushkar Dakle, Janani Sundaresan, Ngan B Doan, Masashi Sanada, Aiko Sato-Otsubo, Manja Meggendorfer, Henry Yang, Jonathan W Said, Seishi Ogawa, Torsten Haferlach, Der-Cherng Liang, Lee-Yung Shih, Tsuyoshi Nakamaki, Q Tian Wang, H Phillip Koeffler
Chromosomal translocation t(8;21)(q22;q22) which leads to generation of oncogenic RUNX1-RUNX1T1 (AML1-ETO) fusion is observed in about 10% of acute myelogenous leukemia (AML). To uncover somatic mutations that cooperate with t(8;21)-driven leukemia, we performed whole and targeted exome sequencing of an Asian cohort at diagnosis and relapse. We identified high frequency of truncating alterations in ASXL2 along with recurrent mutations of KIT, TET2, MGA, FLT3, and DHX15 in this subtype of AML. To investigate in-depth the role of ASXL2 in normal hematopoiesis, we utilized a mouse model of ASXL2 deficiency...
August 9, 2018: Haematologica
https://www.readbyqxmd.com/read/30089953/cytodiagnosis-of-coexistence-of-leukemic-infiltration-and-extramedullary-hematopoiesis-in-a-cervical-lymph-node-in-t-cell-leukemia-patient
#13
Akanksha Bothale, Kalpana Bothale, Sadhana Mahore, Trupti Dongre
Extramedullary hematopoiesis (EMH) is a compensatory mechanism that occurs when the marrow is unable to maintain sufficient red cell mass. EMH generally occurs in the patients with deficient bone marrow hematopoiesis secondary to either peripheral red cell destruction or marrow replacement. Although EMH is known to occur in agnogenic myeloid metaplasia with myelofibrosis, chronic myelogenous leukemia, thalassemia, and infiltrative disorders, such as lymphomas, it is rare in acute leukemias. EMH is most commonly seen in the liver and spleen as a diffuse lesion...
July 2018: Journal of Cytology
https://www.readbyqxmd.com/read/30086328/high-mobility-group-box-1-protein-mediated-necroptosis-contributes-to-dasatinib-induced-cardiotoxicity
#14
Zhifei Xu, Ying Jin, Hao Yan, Zizheng Gao, Bo Xu, Bo Yang, Qiaojun He, Qiang Shi, Peihua Luo
Dasatinib shows remarkable activity against imatinib-refractory chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). However, severe cardiovascular toxicity limits the clinical applications of dasatinib. Since the underlying mechanism of dasatinib-induced cardiotoxicity is still elusive, we aim to clarify this. Recent studies have shown that necroptosis and apoptosis participate in multiple toxicity development. Here, we first report that dasatinib could directly induce cardiomyocytes death, as analyzed by the Sulforhodamine B (SRB) assay...
October 15, 2018: Toxicology Letters
https://www.readbyqxmd.com/read/30083851/c-terminal-runx1-mutation-in-familial-platelet-disorder-with-predisposition-to-myeloid-malignancies
#15
Kateřina Staňo Kozubík, Lenka Radová, Michaela Pešová, Kamila Réblová, Jakub Trizuljak, Karla Plevová, Veronika Fiamoli, Jaromír Gumulec, Helena Urbánková, Tomáš Szotkowski, Jiří Mayer, Šárka Pospíšilová, Michael Doubek
Here we report a C-terminal RUNX1 mutation in a family with platelet disorder and predisposition to myeloid malignancies. We identified the mutation c.866delG:p.Gly289Aspfs*22 (NM_001754) (RUNX1 b-isoform NM_001001890; c.785delG:p.Gly262Aspfs*22) using exome sequencing of samples obtained from eight members of a single family. The mutation found in our pedigree is within exon eight and the transactivation domain of RUNX1. One of the affected individuals developed myelodysplastic syndrome (MDS), which progressed to acute myelogenous leukemia (AML)...
August 6, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/30083633/severe-intracranial-hemorrhage-at-initial-presentation-of-acute-myelogenous-leukemia
#16
Amanda Balmages, Joseph Dinglasan, Megan Boysen Osborn
Intracranial hemorrhage (ICH) is the second leading cause of mortality among patients diagnosed with acute myelogenous leukemia (AML). The bone marrow failure associated with AML produces dysfunctional platelets, which significantly increases the risk of hemorrhagic complications within this population. In this report we discuss the case of a previously healthy female patient, newly diagnosed with AML, who rapidly developed fatal ICH.
August 2018: Clinical practice and cases in emergency medicine
https://www.readbyqxmd.com/read/30082223/wilms-tumor-1-expression-at-diagnosis-correlates-with-genetic-abnormalities-and-polymorphism-but-is-not-independently-prognostic-in-acute-myelogenous-leukemia-a-hokkaido-leukemia-net-study
#17
Daisuke Hidaka, Masahiro Onozawa, Junichi Hashiguchi, Naohiro Miyashita, Kohei Kasahara, Shinichi Fujisawa, Eiko Hayase, Kohei Okada, Souichi Shiratori, Hideki Goto, Junichi Sugita, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Tomoyuki Endo, Satoshi Yamamoto, Yutaka Tsutsumi, Yoshihito Haseyama, Takahiro Nagashima, Akio Mori, Shuichi Ota, Hajime Sakai, Toshimichi Ishihara, Kiyotoshi Imai, Takuto Miyagishima, Yasutaka Kakinoki, Mitsutoshi Kurosawa, Hajime Kobayashi, Hiroshi Iwasaki, Chikara Shimizu, Takeshi Kondo, Takanori Teshima
BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. PATIENTS AND METHODS: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients...
July 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/30078796/-fgfr1-mutated-b-cell-acute-lymphoblastic-leukemia-transforming-to-myelodysplastic-myeloproliferative-neoplasm-and-acute-myeloid-leukemia
#18
Shiro Ide, Shin Ohara, Morihiro Inoue, Jian Hua, Masao Hagihara
A 77-year-old male with hyperleukocytosis and thrombocytopenia was diagnosed with Philadelphia chromosome (Ph) -negative B-cell acute lymphoblastic leukemia (ALL) ; he was treated with induction chemotherapy. Despite an initial complete remission, hyperleukocytosis was returned 18 months later. A bone marrow smear revealed a substantial increase in the number of myeloid cells with each stage of differentiation, which was markedly different from the initial presentation, resulting in the diagnosis of Ph-negative myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN)...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/30077464/association-between-renal-cell-carcinoma-and-myelodysplastic-syndromes-epigenetic-underpinning
#19
Niraj Shenoy, Mythri Mudireddy, Rangit Vallapureddy, Nelson Leung, Lance Pagliaro, Thomas Witzig, Fang-Shu Ou, Tamas Ordog, John Cheville, Mrinal Patnaik, R Houston Thompson, Ayalew Tefferi, Kebede Begna
BACKGROUND: Renal cell carcinoma (RCC) and certain myeloid malignancies are both characterized by widespread aberrant DNA hypermethylation. After clinical observations of patients with a personal history of both malignancies, we sought to explore a potential association, and to describe the clinical characteristics of these patients. PATIENTS AND METHODS: Mayo Clinic's 'Advanced Cohort Explorer' database was used to identify patients with a history of both malignancies...
June 28, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/30076185/upper-gastrointestinal-acute-graft-versus-host-disease-adds-minimal-prognostic-value-in-isolation-or-with-other-graft-versus-host-disease-symptoms-as-currently-diagnosed-and-treated
#20
Sarah Nikiforow, Tao Wang, Michael Hemmer, Stephen Spellman, Görgün Akpek, Joseph H Antin, Sung Won Choi, Yoshihiro Inamoto, Hanna J Khoury, Margaret MacMillan, David I Marks, Ken Meehan, Hideki Nakasone, Taiga Nishihori, Richard Olsson, Sophie Paczesny, Donna Przepiorka, Vijay Reddy, Ran Reshef, Hélène Schoemans, Ned Waller, Daniel Weisdorf, Baldeep Wirk, Mary Horowitz, Amin Alousi, Daniel Couriel, Joseph Pidala, Mukta Arora, Corey Cutler
Upper gastrointestinal acute graft- versus -host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft- versus -host disease. Currently classified as Grade II in consensus criteria, upper gastrointestinal acute graft- versus -host disease is often treated with systemic immunosuppression. We reviewed the Center for International Blood and Marrow Transplant Research database to assess the prognostic implications of upper gastrointestinal acute graft- versus -host disease in isolation or with other acute graft- versus -host disease manifestations...
October 2018: Haematologica
keyword
keyword
161148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"